Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

The biotech sector witnessed a series of events over the past week. The FDA accepted Alkermes’ new drug application (“NDA”) for ALKS 5461. This provided a major a boost to the company’s stock. However, Celldex’s breast cancer study failed to meet the primary endpoint owing to which the stock plummeted significantly.

In another news, Alexion announced plans to acquire Wilson Therapeutics for $855 million. Thus, the space remained one of the key areas of investors focus.